我要投票 钙立速在补钙行业中的票数:462
· 外 推 电 报 ·
2025-09-09 17:07:56 星期二

【钙立速是哪个国家的品牌?】

钙立速是什么牌子?「钙立速」是 三亚百泰生物科技有限公司 旗下著名品牌。该品牌发源于海南,由创始人张立在2010期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力钙立速品牌出海!将品牌入驻外推网,定制钙立速品牌推广信息,可以显著提高钙立速产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

钙立速-纳米天门冬氨酸螯合钙使用的是气穴崩塌原理,使天门冬氨酸和氢氧化钙充分进行乳化分散,纳米破碎,颗粒度达2-80纳米,可以被小肠粘膜细胞识别直接吸收,不需添加维生素D3的强化,吸收率达90%以上,改善了现代人体对钙的需求。

公司研发生产的纳米氨基酸螯合钙将打造成纳米螯合技术发展的核心和主流方向,改变传统钙的吸收问题和人体吸收过程中的副作用问题,此项生产工艺已获得国家专利,在纳米螯合钙技术上取得重大突破,并已被市场广泛接受及应用。

三亚百泰生物科技有限公司,是一家集研发、生产、销售为一体的高新技术企业,公司以“资源优化整合,发挥联动互效”为宗旨,努力促进以科技与产业接轨、产品与市场接轨的系统工程,公司积极开展国际化技术转化的同时,专注于培育自主创新能力,多年来组织多学科专家连续进行前期试验和研发工作,在一批学者的共同努力下,先后研制出L-天门冬氨酸纳米螯合钙、土壤保墒材料和果蔬保鲜技术等一系列科研成果。正在开发的新产品包括纳米材料、南药研发、土壤保墒、海洋生物等方面,专注创新的研发成果将为国人创造无限价值。百泰生物科技有限公司现有员工50多名,大学本科占80%以上,其中科研人员占50%以上。

公司研发生产的纳米天门冬氨酸螯合钙使用的是气穴崩塌原理,使天门冬氨酸和氢氧化钙充分进行乳化分散,纳米破碎,颗粒度达2-80纳米,可以被小肠粘膜细胞识别直接吸收,不需添加维生素D3的强化,吸收率达90%以上,改善了现代人体对钙的需求。公司研发生产的纳米氨基酸螯合钙将打造成纳米螯合技术发展的核心和主流方向,改变传统钙的吸收问题和人体吸收过程中的副作用问题,此项生产工艺已获得国家专利,在纳米螯合钙技术上取得重大突破,并已被市场广泛接受及应用。

公司利用新一代纳米技术,结合海南南药及海洋生物的优势,将不断研制出更多新产品,同时开拓纳米技术在中药领域的应用,加快推进‘纳米中药’从理论变为现实的进程,突破创新的研发成果将为国人创造价值,在实现经济效益的同时创造更高的社会效益。

目前三亚百泰生物科技有限公司在三亚创意产业园投资生产基地的二期建设项目,完全建成后的纳米氨基酸螯合钙生产基地年产量为 1200 吨,执照打造成大型的纳米螯合钙生产基地,为我国食品、乳制品行业从传统产品向功能产品的转化提供坚实后盾;为医药中间体的发展,提供新型科技成果、新型的原料保障。

英文翻译:Calcium standing speed - nanometer aspartic acid chelate calcium uses the principle of cavitation collapse, which makes aspartic acid and calcium hydroxide fully emulsified and dispersed, nanometer broken, particle size up to 2-80 nm, which can be recognized and directly absorbed by small intestinal mucosal cells, without adding vitamin D3 to strengthen, and the absorption rate is over 90%, which improves the demand of modern human body for calcium. The nano amino acid chelated calcium developed and produced by the company will be the core and mainstream direction of the development of nano chelating technology, which will change the absorption of traditional calcium and the side effects in the absorption process of human body. This production process has obtained national patent, made a major breakthrough in nano chelated calcium Technology, and has been widely accepted and applied in the market. Sanya Baitai Biotechnology Co., Ltd. is a high-tech enterprise integrating R & D, production and sales. With the tenet of "optimizing and integrating resources, giving full play to linkage and mutual effect", the company strives to promote systematic engineering integrating technology with industry, products with market. While actively carrying out international technology transformation, the company focuses on cultivating independent innovation ability. Over the years, the company Organize multi-disciplinary experts to carry out the preliminary test and research and development work continuously. With the joint efforts of a group of scholars, a series of scientific research achievements have been successively developed, such as L-aspartic acid nano chelate calcium, soil moisture preservation materials, fruits and vegetables preservation technology. The new products under development include nano materials, research and development of South medicine, soil moisture conservation, marine biology, etc. the research and development achievements focused on innovation will create infinite value for Chinese people. Baitai Biotechnology Co., Ltd. has more than 50 employees, more than 80% of which are undergraduates, and more than 50% of which are scientific researchers. The nano-sized calcium aspartate chelate developed and produced by the company is based on the principle of cavitation collapse, which enables the full emulsification and dispersion of aspartic acid and calcium hydroxide. The nano particle size is up to 2-80 nm, which can be recognized and directly absorbed by the intestinal mucosal cells without the reinforcement of vitamin D3. The absorption rate is up to 90%, which improves the demand of modern human body for calcium. The nano amino acid chelated calcium developed and produced by the company will be the core and mainstream direction of the development of nano chelating technology, which will change the absorption of traditional calcium and the side effects in the absorption process of human body. This production process has obtained national patent, made a major breakthrough in nano chelated calcium Technology, and has been widely accepted and applied in the market. Using the new generation of nanotechnology, combined with the advantages of Hainan Southern medicine and marine biology, the company will continue to develop more new products, at the same time, expand the application of nanotechnology in the field of traditional Chinese medicine, accelerate the process of "nano traditional Chinese medicine" from theory to reality, and the breakthrough of innovative research and development results will create value for Chinese people and create higher social benefits while realizing economic benefits. At present, Sanya Baitai Biotechnology Co., Ltd. has invested in the second phase of the production base of Sanya creative industrial park. The annual output of the completed nano amino acid calcium chelate production base is 1200 tons. The license has been built into a large-scale nano calcium chelate production base, providing solid support for the transformation of China's food and dairy industry from traditional products to functional products, and for the transformation of pharmaceutical intermediates To provide new scientific and technological achievements and new material guarantee.

本文链接: https://www.waitui.com/brand/a6f0f985f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

高测股份:已推出适用于人形机器人灵巧手的复合金属腱绳,并形成小批量订单

36氪获悉,高测股份公告,公司已成功推出适用于人形机器人灵巧手及其他部位的复合金属腱绳,并已形成小批量订单。针对灵巧手高自由度要求,公司主推复合钨丝腱绳,复合钨丝腱绳具备极小的折弯半径,独特分子结构设计具备更优耐磨及耐疲劳性能,能为人形机器人灵巧手绳驱方案提供更可靠、耐久且精准的动力传输和高自由度解决方案,受到客户高度认可,已进入多家机器人相关企业试用,并已与国内头部企业开展深入研发合作。

2小时前

特斯拉推出升级版Megapack 3

周一,特斯拉在拉斯维加斯举行的“Las Megas”活动上发布了Megapack 3和Megablock,该公司表示,其升级版Megapack 3使用了“大幅简化的热舱,减少了78%的连接”,并表示将于2026年底在休斯顿生产。(新浪财经)

2小时前

摩根士丹利:预计到2040年,中国药物将占美国FDA批准药物的35%

摩根士丹利近日发布深度研报称,预计到2040年,源自中国的药物在美国食品药品监督管理局(FDA)获批的比例将从目前的5%提升至35%,并将在中国以外市场创造约2200亿美元的收入。预计得益于中国在药物研发方面的速度和成本优势,到2040年全球研发回报率将提高48%。摩根士丹利还称,全球制药行业正面临一项迫在眉睫的挑战:到2035年,因专利到期(LOE)导致的收入损失预计将高达1150亿美元。(财联社)

2小时前

动力新科:上海微电子借壳动力新科上市消息不实

36氪获悉,针对投资者关于“据消息称上海微电子正在策划借壳动力新科上市,这是巧合还是提前安排重组事宜?”的提问,动力新科在互动平台回应称,上述消息不实。

2小时前

消息称英伟达要求三星翻倍供应GDDR7

据业内人士消息,英伟达已要求三星翻倍供应GDDR7,三星的扩产准备工作已基本完成,预计扩大后的供应链最早将于本月开始运营。据了解,英伟达要求三星提高GDDR7供应量,主要是为了AI加速器需求。 (财联社)

2小时前

本页详细列出关于钙立速的品牌信息,含品牌所属公司介绍,钙立速所处行业的品牌地位及优势。
咨询